DRG 492 Overview

DRG 492 covers hospital admissions for lower extremity and humerus surgical procedures excluding hip, foot, and femur when a Major Complication or Comorbidity is present. Cases typically include complex open or revision procedures, perioperative complications, or significant comorbid conditions that increase resource use. This Diagnosis-Related Group matters for Medicare payment because the presence of a Major Complication or Comorbidity elevates the relative weight and inpatient reimbursement. Accurate coding of procedures and accompanying Major Complication or Comorbidity diagnoses directly affects payment for higher-acuity surgical admissions.

• Acute perioperative optimization trials evaluating interventions to reduce major complications in patients undergoing lower extremity or humerus procedures (excluding hip, foot, and femur) with major comorbidities: these randomized or pragmatic trials focus on patients admitted for open or arthroscopic procedures such as knee reconstructions, tibial plateau repairs, or complex humeral fracture fixation who also have significant comorbid illness (eg, advanced cardiac, pulmonary, renal disease). The studies test protocols for perioperative risk stratification, enhanced monitoring, and bundled early interventions (fluid management, goal-directed hemodynamics, early respiratory support) to reduce in-hospital mortality and MCC-driven complications; results are directly relevant to surgeons, hospitalists, and payers because reducing acute complications shortens length of stay and lowers high-cost resource utilization.
• Comparative effectiveness research of surgical techniques and implant strategies in complex lower extremity and humerus procedures in high-risk inpatients: cohort studies and randomized registry trials compare approaches such as open reduction internal fixation versus intramedullary fixation, the use of supplemental fixation or bone grafting, and timing of definitive fixation in patients with diabetes, peripheral vascular disease, or active infection. These studies enroll the heterogeneous, comorbid population typical of DRG 492 to evaluate outcomes including in-hospital complication rates, need for reoperation during the index admission, and short-term functional recovery; findings inform clinical pathways, coding/DRG assignment considerations for severity, and payer decisions about reimbursement for higher-cost implants or staged care.
• Post-discharge outcomes and readmission prevention studies targeting patients discharged after lower extremity or humerus procedures with prior in-hospital MCCs: prospective observational studies and interventional transitional-care trials test discharge bundles, home-based rehabilitation, and remote monitoring for wound infection, anticoagulation adherence, and mobility in patients who had major inpatient complications. Because readmissions and early post-discharge adverse events drive cumulative episodes of care cost and affect bundled payment calculations, this research helps providers and payers identify which discharge practices reduce 30-day readmissions, post-acute facility use, and long-term disability for this high-risk DRG population.